The funding round values the company at $2 billion as it pushes forward treatments for skin conditions and weight-loss maintenance after stopping GLP-1 drugs.
The maker of Advil is capitalizing on the popularity of GLP-1 weight-loss medications, according to a report by CNBC.
The investment bank raised its rating on the pharmaceutical company to "buy" from "hold," pointing to continued momentum in weight-loss and diabetes drugs.
Research cited by Scientific American found that giving older mice the GLP-1 drug semaglutide, sold as Wegovy or Ozempic, notably extended their lifespan, though implications for humans remain unclear.